Shrikant Anant

Professional Background

Dr. Anant earned a B.Sc. in zoology and a M.Sc. in medical microbiology from the University of Madras in India, a M.Sc. in microbiology from Michigan State University, and a PhD in molecular genetics from the University of Illinois at Chicago. Dr. Anant joined The University of Kansas Cancer Center in 2010 after serving as associate professor and director of gastroenterology research at the University of Oklahoma Health Sciences Center in Oklahoma City. He led a team of researchers who discovered a new gene, RBM3, which can cause normal cells to turn into cancer cells; also, stopping RBM3's expression in cancer cells causes the cancer cells to die. Earlier, while serving as assistant professor at Washington University School of Medicine, he discovered the first tumor-suppressing RNA-binding protein. Subsequently, he discovered the rare, quiescent cancer stem cells in colon and pancreatic cancers. Dr. Anant was a key figure in the discovery and development of Ciclopirox Prodrug, KU Cancer Center's first anticancer drug to go from bench to bedside. He was also the recipient of the 2017 KU Chancellors Club Research Award.

• BS, University of Madras
• MS, University of Madras
• MS, Michigan State Univ.
• PhD, Univ. of Illinois-Chicago

• American College of Nutrition, Fellow, 2014 - Present
• American Society of Preventive Oncology, Member, 2013 - 2017
• American Society for Biochemistry and Molecular Biology, Member, 2012 - Present
• American Physiological Society, Member, 2010 - Present
• Gastroenterology Research Group, Member, 2006 - 2010
• American Association of Cancer Research, Member, 2000 - Present